Streetbeat News

ZURA

Zura Bio Limited

https://zurabio.com

Industry

Biotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Open

3.15

Mkt cap

200M

Volume

71K

High

3.30

P/E Ratio

-7.85

52-wk high

6.35

Low

3.00

Div yield

N/A

52-wk low

2.00

Cantor Fitzgerald has initiated coverage on Zura Bio (NASDAQ:ZURA) with an Overweight rating, as per analyst Josh Schimmer.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:43 am

Zura Bio Limited (NASDAQ:ZURA) will present data on its dual-pathway antibody tibulizumab (ZB-106) for Sjogren's syndrome and rheumatoid arthritis at the EULAR 2024 conference in Vienna.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:06 am

Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Zura Bio (NASDAQ:ZURA) and increased the price target from $16 to $21.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 4:48 pm

Zura Bio reported Q1 2024 GAAP EPS of $(0.02), surpassing the analyst consensus estimate of $(0.23) by 91.3 percent, indicating a significantly better financial performance than expected.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 10:16 am

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Zura Bio (NASDAQ:ZURA) with an Overweight rating and a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 9:36 am

In Friday's intraday session, several health care stocks showed significant movement. Biodexa Pharmaceuticals, Agenus, Sunshine Biopharma, Cullinan Therapeutics, ImmunityBio, and Zura Bio were among the gainers with notable percentage increases in their stock prices. Conversely, Nuwellis, IMAC Holdings, NKGen Biotech, Aclarion, Accolade, and X4 Pharmaceuticals experienced declines. Accolade's drop was highlighted alongside its Q4 earnings report release.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:31 pm

Zura Bio's stock is trading higher following the announcement of an oversubscribed $112.5 million private placement.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:36 pm

Zura Bio Limited (NASDAQ:ZURA) announced a $112.5M private placement of 20.1M Class A shares at $3.108 each to fund operations through 2027. The placement, led by Access Biotechnology and other major investors, aims to accelerate the development of tibulizumab for autoimmune diseases. The deal, expected to close on April 22, 2024, includes pre-funded warrants and is in compliance with Nasdaq rules. Piper Sandler, Guggenheim Securities, and Cantor are the lead placement agents.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 1:23 pm

Zura Bio announced Robert Lisicki as its new CEO and Director, succeeding founding CEO Dr. Someit Sidhu, who remains a Board Director. Lisicki brings nearly 30 years of R&D, commercial, and global executive experience, particularly in I&I therapies.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 10:11 am

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on Zura Bio (NASDAQ:ZURA) but has lowered the price target from $17 to $16.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.